Overview
- Peptide (C)KTSNIRANFENLAK, corresponding to amino acid residues 346 - 359 of mouse Cortactin (Accession Q60598). Intracellular.
- Rat and mouse brain lysates; human K562 erythroleukemia, HeLa cervical adenocarcinoma, U-87MG glioblastoma, and MCF-7 breast adenocarcinoma cell lysates (1:200-1:5000).
Western blot analysis of rat brain lysate (lanes 1 and 3) and mouse brain lysate (lanes 2 and 4):1, 2. Anti-Cortactin Antibody (#APZ-018), (1:1000).
3, 4. Anti-Cortactin Antibody, preincubated with Cortactin Blocking Peptide (#BLP-PZ018).
Cortical acting binding protein, Cortactin, is an actin-binding protein involved in cytoskeletal regulation1. Cortactin is a 63–65 kDa protein that consists of four major domains: N-terminal acidic (NTA), 6.5 tandems repeat, proline-rich domain, and the C-terminal Src homology 3 domains (SH3 domains)2 and it is regulated by post translational modifications such as phosphorylation and acetylation1.
The actin filament network provides mechanical support as well as protrusive and contractile forces essential for directed cell motility and cell and tissue morphogenesis. Cortactin activates the Arp2/3 complex, the main regulator of actin polymerization, and thereby regulates the assembly of branched actin3.
Overexpression of cortactin was shown to enhance cell migration, invasion, and tumor cell metastasis. It is also overexpressed in various types of cancer such as breast cancers as well as head and neck tumors1.
